The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper

Vaccine

Volumn 33, Issue , 2015, Pages F1-F67

  Halsey, Neal A ^a   Talaat, Kawsar R ^a   Greenbaum, Adena ^b   Mensah, Eric ^a   Dudley, Matthew Z ^a   Proveaux, Tina ^a   Salmon, Daniel A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADEM; Bell's palsy; Cellulitis like reactions; Febrile seizures; Fever; Guillain Barre syndrome; Hypersensitivity reactions; Inflammatory arthritis; Influenza; Influenza vaccine; ITP; Local reactions following IIV; Malaise; Multiple sclerosis; Myalgia; Narcolepsy; Vaccine safety

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; LIVE VACCINE;

2009 H1N1 INFLUENZA; ACUTE DISSEMINATED ENCEPHALOMYELITIS; ALLERGIC REACTION; BELL PALSY; BURSITIS; CELLULITIS; DRUG SAFETY; EMBASE; FEBRILE CONVULSION; FEVER; GUILLAIN BARRE SYNDROME; HOSPITALIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MEDLINE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MYALGIA; NARCOLEPSY; NONHUMAN; PANDEMIC INFLUENZA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHEUMATOID ARTHRITIS; SHOULDER INJURY; SYSTEMATIC REVIEW (TOPIC); WHEEZING; ADVERSE EFFECTS; CHEMICALLY INDUCED; HYPERSENSITIVITY; INFANT; INFLUENZA, HUMAN; ORGANIZATION; PRESCHOOL CHILD; PRODUCT SAFETY; RISK ASSESSMENT; STANDARDS; VACCINATION;

ACADEMIES AND INSTITUTES; CHILD, PRESCHOOL; CONSUMER PRODUCT SAFETY; FEVER; HUMANS; HYPERSENSITIVITY; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; RISK ASSESSMENT; SEIZURES, FEBRILE; VACCINATION; VACCINES, ATTENUATED;

EID: 84975687600     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.080     Document Type: Review

References (395)

1. Poehling K.A., Edwards K.M., Griffin M.R., Szilagyi P.G., Staat M.A., Iwane M.K., et al. The burden of influenza in young children, 2004-2009. Pediatrics 2013, 131(2):207-216.
2. Harris T., Wong K., Stanford L., Fediurek J., Crowcroft N., Deeks S. Did narcolepsy occur following administration of AS03-adjuvanted A(H1N1) pandemic vaccine in Ontario Canada? A review of post-marketing safety surveillance data. Euro Surveill 2014, 19(36).
3. Halsey N.A. The science of evaluation of adverse events associated with vaccination. Semin Pediatr Infect Dis 2002, 13(3):205-214.
4. Tozzi A.E., Asturias E.J., Balakrishnan M.R., Halsey N.A., Law B., Zuber P.L. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine 2013, 31(44):5041-5046.
5. World Health Organization/Global Vaccine Safety Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO AEFI causality assessment classification 2013, Available online at: http://www.who.int/vaccine_safety/publications/gvs_aefi/en/ [accessed 26.05.15].
6. Weldeselassie Y.G., Whitaker H.J., Farrington C.P. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect 2011, 139(12):1805-1817.
7. Institute of Medicine Adverse effects of vaccines: evidence and causality 2012, The National Academies Press, Washington, DC.
8. Girard M.P., Plotkin S.A. HIV vaccine development at the turn of the 21st century. Curr Opin HIV AIDS 2012, 7(1):4-9.
9. Polack F.P. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr Res 2007, 62(1):111-115.
10. Wood R.A., Berger M., Dreskin S.C., Setse R., Engler R.J., Dekker C.L., et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 2008, 122(3):e771-e777.
11. CIOMS Frequency of adverse drug reactions. Guidelines for preparing core clinical safety information on drugs report from CIOMS working group III, Geneva 1995.
12. Dormitzer P.R., Tsai T.F., Del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012, 8(1):45-58.
13. Huber V.C. Influenza vaccines: from whole-virus preparations to recombinant protein technology. Expert Rev Vaccines 2014, 13(1):31-42.
14. Vajo Z., Kosa L., Szilvasy I., Pauliny Z., Bartha K., Visontay I., et al. Yearly licensing studies from 1997 to 2007 of the inactivated whole-virus seasonal influenza vaccine fluval - a useful approach to pandemic vaccine development even in less well developed countries?. Influenza Other Respir Viruses 2008, 2(6):221-228.
15. Loew-Baselli A., Pavlova B.G., Fritsch S., Poellabauer E.M., Draxler W., Kistner O., et al. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory. Vaccine 2012, 30(41):5956-5966.
16. Waddington C.S., Walker W.T., Oeser C., Reiner A., John T., Wilkins S., et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
17. Nicholson K.G., Abrams K.R., Batham S., Clark T.W., Hoschler K., Lim W.S., et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011, 11(2):91-101.
18. Kulkarni P.S., Manjunath K., Agarkhedkar S., Group of SII IIV Studies Safety and immunogenicity of an adjuvanted whole virion, inactivated A (H1N1) 2009 influenza vaccine in young and elderly adults, and children. Vaccine 2012, 31(1):20-22.
19. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375(9708):56-66.
20. ®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011, 29(44):7733-7739.
21. van der Velden M.V., Fritz R., Pöllabauer E.M., Portsmouth D., Howard M.K., Kreil T.R., et al. Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. J Infect Dis 2014, 209(1):12-23.
22. Sansyzbay A.R., Erofeeva M.K., Khairullin B.M., Sandybayev N.T., Kydyrbayev Z.K., Mamadaliyev S.M., et al. An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans. Clin Vaccine Immunol 2013, 20(8):1314-1319.
23. Hoa L.K., Hiep L.V., Be L.V. Development of pandemic influenza vaccine production capacity in Viet Nam. Vaccine 2011, 29(Suppl. 1):A34-A36.
24. Li H., Guo X.J., Ye X.F., Jiang H., Du W.M., Xu J.F., et al. Adverse drug reactions of spontaneous reports in shanghai pediatric population. PLOS ONE 2014, 9(2):e89829.
25. Reisinger K.S., Block S.L., Izu A., Groth N., Holmes S.J. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009, 200(6):849-857.
26. Rowhani-Rahbar A., Klein N.P., Baxter R. Assessing the safety of influenza vaccination in specific populations: children and the elderly. Expert Rev Vaccines 2012, 11(8):973-984.
27. Rowhani-Rahbar A., Klein N.P., Dekker C.L., Edwards K.M., Marchant C.D., Vellozzi C., et al. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine 2012, 31(1):271-277.
28. Cook I.F. An evidence based protocol for the prevention of upper arm injury related to vaccine administration (UAIRVA). Hum Vaccin 2011, 7(8):845-848.
29. Pavia-Ruz N., Angel Rodriguez Weber M., Lau Y.L., Nelson E.A., Kerdpanich A., Huang L.M., et al. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother 2013, 9(9):1978-1988.
30. Vesikari T., Groth N., Karvonen A., Borkowski A., Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009, 27(45):6291-6295.
31. Vesikari T., Block S.L., Guerra F., Lattanzi M., Holmes S., Izu A., et al. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 2012, 31(5):494-500.
32. Durando P., Icardi G., Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010, 10(4):639-651.
33. Jackson L.A., Chen W.H., Stapleton J.T., Dekker C.L., Wald A., Brady R.C., et al. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis 2012, 206(6):811-820.
34. Law B., Lafleche J. Cellulitis reported to the Canadian adverse events following immunization surveillance system (1987-2012). Pharmacoepidemiol Drug Saf 2013, 22(Suppl. 1):255-256.
35. Burwen D.R., La Voie L., Braun M.M., Houck P., Ball R. Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol Drug Saf 2007, 16(7):753-761.
36. Owensby J.E., Elliott S., Tu K., Hernandez J.E. Cellulitis and myositis caused by Agrobacterium radiobacter and Haemophilus parainfluenzae after influenza virus vaccination. South Med J 1997, 90(7):752-754.
37. Ben-Shoshan M., Lejtenyi C., Primeau M.N. The predilection of chickenpox exanthema to influenza vaccine injection site. Pediatr Dermatol 2009, 26(4):481-482.
38. Demoly P., Tanno L.K., Akdis C.A., Lau S., Calderon M.A., Santos A.F., et al. Global classification and coding of hypersensitivity diseases - an EAACI - WAO survey, strategic paper and review. Allergy 2014, 69(5):559-570.
39. Dhami S., Panesar S.S., Roberts G., Muraro A., Worm M., Bilò M.B., et al. Management of anaphylaxis: a systematic review. Allergy 2014, 69(2):168-175.
40. Simons F.E., Ardusso L.R., Bilò M.B., Cardona V., Ebisawa M., El-Gamal Y.M., et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014, 7(1):9.
41. Galli S.J., Tsai M. IgE and mast cells in allergic disease. Nat Med 2012, 18(5):693-704.
42. Commins S.P., Platts-Mills T.A. Delayed anaphylaxis to red meat in patients with IgE specific for galactose alpha-1,3-galactose (alpha-gal). Curr Allergy Asthma Rep 2013, 13(1):72-77.
43. Wood R.A. Allergic reactions to vaccines. Pediatr Allergy Immunol 2013, 24(6):521-526.
44. Kelso J.M. Administering influenza vaccine to egg-allergic persons. Expert Rev Vaccines 2014, 13(8):1049-1057.
45. Institute for Vaccine Safety Allergens table 2013, Available at http://vaccinesafety.edu/components-Allergens.htm.
46. Smith C.C. Risk of latex allergy from medication vial closures. Ann Pharmacother 1999, 33(3):373-374.
47. Mark C. Large variations in the ovalbumin content in six European influenza vaccines. Pharmeur Sci Notes 2006, 2006(1):27-29.
48. McKinney K.K., Webb L., Petersen M., Nelson M., Laubach S. Ovalbumin content of 2010-2011 influenza vaccines. J Allergy Clin Immunol 2011, 127(6):1629-1632.
49. Kelso J.M., Greenhawt M.J., Li J.T., Nicklas R.A., Bernstein D.I., Blessing-Moore J., et al. Adverse reactions to vaccines practice parameter 2012 update. J Allergy Clin Immunol 2012, 130:25-43.
50. Grohskopf L.A., Olsen S.J., Sokolow L.Z., Bresee J.S., Cox N.J., Broder K.R., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2014-15 influenza season. Morb Mortal Wkly Rep 2014, 63(32):691-697.
51. Owens G., MacGinnitie A. Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy. J Allergy Clin Immunol 2011, 127:264-265.
52. Rouleau I., De Serres G., Skowronski D.M., Drolet J.P., Lemire C., Toth E., et al. Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada. Vaccine 2014, 32(28):3480-3487.
53. Seitz C.S., Bröcker E.B., Trautmann A. Vaccination-associated anaphylaxis in adults: diagnostic testing ruling out IgE-mediated vaccine allergy. Vaccine 2009, 27(29):3885-3889.
54. Rouleau I., De Serres G., Drolet J.P., Banerjee D., Lemire C., Moore A., et al. Allergic symptoms after pandemic influenza vaccination rarely mediated by vaccine-specific IgE. J Allergy Clin Immunol 2012, 130(6):1423-1426.
55. Bonds R.S., Kelly B.C. Severe serum sickness after H1N1 influenza vaccination. Am J Med Sci 2013, 345(5):412-413.
56. Kemp S.F., Lockey R.F. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002, 110(3):341-348.
57. De Serres G., Grenier J.L., Toth E., Ménard S., Roussel R., Tremblay M., et al. The clinical spectrum of the oculo-respiratory syndrome after influenza vaccination. Vaccine 2003, 21(19-20):2354-2361.
58. De Serres G., Toth E., Ménard S., Grenier J.L., Roussel R., Tremblay M., et al. Oculo-respiratory syndrome after influenza vaccination: trends over four influenza seasons. Vaccine 2005, 23(28):3726-3732.
59. Babiuk S., Skowronski D.M., De Serres G., HayGlass K., Brunham R.C., Babiuk L. Aggregate content influences the Th1/Th2 immune response to influenza vaccine: evidence from a mouse model. J Med Virol 2004, 72(1):138-142.
60. Skowronski D.M., Bjornson G., Husain E., Metzger D.L., Scheifele D.W. Oculorespiratory syndrome after influenza immunization in children. Pediatr Infect Dis J 2005, 24(1):63-69.
61. National Advisory Committee on Immunization (NACI), An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) Supplementary Statement for the 2001-2002 season: influenza vaccination of persons who experienced oculo-respiratory syndrome following previous influenza vaccination. Can Commun Dis Rep 2001, 27:1-7.
62. Halsey N.A., Griffioen M., Dreskin S.C., Dekker C.L., Wood R., Sharma D., et al. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS. Vaccine 2013, 31(51):6107-6112.
63. National Advisory Committee on Immunization (NACI) Statement on influenza vaccination for the 2003-2004 season. Can Commun Dis Rep 2003, 29:1-20.
64. van der Tweel I., Askie L., Vandermeer B., Ellenberg S., Fernandes R.M., Saloojee H., et al. Standard 4: determining adequate sample sizes. Pediatrics 2012, 129(Suppl. 3):S138-S145.
65. Lieberman J.A., Sicherer S.H. Diagnosis of food allergy: epicutaneous skin tests, in vitro tests, and oral food challenge. Curr Allergy Asthma Rep 2011, 11(1):58-64.
66. Englund J.A., Walter E., Black S., Blatter M., Nyberg J., Ruben F.L., et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatr Infect Dis J 2010, 29(2):105-110.
67. Mahajan D., Roomiani I., Gold M.S., Lawrence G.L., McIntyre P.B., Menzies R.I. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun Dis Intell Q Rep 2010, 34(3):259-276.
68. Rüggeberg J.U., Gold M.S., Bayas J.M., Blum M.D., Bonhoeffer J., Friedlander S., et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5675-5684.
69. Vidal P., Reyna J., Saldaña P., Richardson V.L. Events temporarily associated with anti-influenza A (H1N1) vaccination in Mexico. Arch Med Res 2011, 42(7):627-632.
70. Banzhoff A., Haertel S., Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 2011, 7(5):539-548.
71. Tavares F., Delaigle A., Slavin D., Bauchau V., Fries L., Seifert H. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective. Vaccine 2011, 29(37):6402-6407.
72. Rouleau I., De Serres G., Drolet J.P., Skowronski D.M., Ouakki M., Toth E., et al. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. Vaccine 2013, 31(50):5989-5996.
73. Kim J.H., Cho H.Y., Hennessey K.A., Lee H.J., Bae G.R., Kim H.C. Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all vaccine recipients and AEFI and the passive surveillance system in South Korea. Jpn J Infect Dis 2012, 65(2):99-104.
74. Izurieta H.S., Haber P., Wise R.P., Iskander J., Pratt D., Mink C., et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005, 294(21):2720-2725.
75. Domingues E., Sweeney S.M., Belazarian L. Gianotti-Crosti syndrome in a child following intranasal influenza virus vaccination. Eur J Pediatr Dermatol 2009, 19(3):143-145.
76. Liu P.Y., Shi Z.Y., Lee C.H. Cutaneous vasculitis following influenza vaccination. Intern Med 2010, 49(19):2187-2188.
77. Iwane M.K., Prill M.M., Lu X., Miller E.K., Edwards K.M., Hall C.B., et al. Human rhinovirus species associated with hospitalizations for acute respiratory illness in young US children. J Infect Dis 2011, 204(11):1702-1710.
78. Watanabe T. Henoch-Schönlein purpura following influenza vaccinations during the pandemic of influenza A (H1N1). Pediatr Nephrol 2011, 26(5):795-798.
79. Marcy S.M., Kohl K.S., Dagan R., Nalin D., Blum M., Jones M.C., et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004, 22(5-6):551-556.
80. Barry D.W., Mayner R.E., Hochstein H.D., Dunlap R.C., Rastogi S.C., Hannah J.E., et al. Comparative trial of influenza vaccines, II. Adverse reactions in children and adults. Am J Epidemiol 1976, 104(1):47-59.
81. Wright P.F., Sell S.H., Thompson J., Karzon D.T. Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants. J Pediatr 1976, 88(1):31-35.
82. Klein N.P., Fireman B., Yih W.K., Lewis E., Kulldorff M., Ray P., et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010, 126(1):e1-e8.
83. Marine W.M., Stuart-Harris C. Reactions and serologic responses in young children and infants after administration of inactivated monovalent influenza A vaccine. J Pediatr 1976, 88(1):26-30.
84. Parkman P.D., Hopps H.E., Rastogi S.C., Meyer H.M. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 1977, 136(Suppl):S722-S730.
85. Wright P.F., Ross K.B., Thompson J., Karzon D.T. Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. N Engl J Med 1977, 296(15):829-834.
86. Wright P.F., Vaughn W.K., Thompson J., Sell S.H., Karzon D.T. Inactivated influenza A/New Jersey/76 vaccines in children: results of a mult-center trial. Dev Biol Stand 1977, 39:309-313.
87. Gonzalez M., Pirez M.C., Ward E., Dibarboure H., García A., Picolet H. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 2000, 83(6):488-491.
88. Bernstein D.I., Zahradnik J.M., DeAngelis C.J., Cherry J.D. Clinical reactions and serologic responses after vaccination with whole-virus or split-virus influenza vaccines in children aged 6 to 36 months. Pediatrics 1982, 69(4):404-408.
89. Public Health Service (PHS) Advisory Committee on Immunization Practices, Center for Disease Control, US Department of Health, Education, and Welfare; Atlanta, Georgia Influenza vaccine: recommendations. Ann Intern Med 1977, 87(3):316-318.
90. Delore V., Salamand C., Marsh G., Arnoux S., Pepin S., Saliou P. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip. Vaccine 2006, 24(10):1586-1592.
91. Skowronski D.M., Jacobsen K., Daigneault J., Remple V.P., Gagnon L., Daly P., et al. Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts. Pediatrics 2006, 117(6):1963-1971.
92. Englund J.A., Walter E.B., Fairchok M.P., Monto A.S., Neuzil K.M. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics 2005, 115(4):1039-1047.
93. Langley J.M., Reich D., Aggarwal N., Connor D., Lebel M.H., Gupta A., et al. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. Pediatr Infect Dis J 2012, 31(8):848-858.
94. Langley J.M., Scheifele D.W., Quach C., Vanderkooi O.G., Ward B., McNeil S., et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine 2012, 30(23):3389-3394.
95. Baxter R., Jeanfreau R., Block S.L., Blatter M., Pichichero M., Jain V.K., et al. evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J 2010, 29(10):924-930.
96. Langley J.M., Carmona Martinez A., Chatterjee A., Halperin S.A., McNeil S., Reisinger K.S., et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 2013, 208(4):544-553.
97. Domachowske J.B., Pankow-Culot H., Bautista M., Feng Y., Claeys C., Peeters M., et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013, 207(12):1878-1887.
98. Greenberg D.P., Robertson C.A., Landolfi V.A., Bhaumik A., Senders S.D., Decker M.D. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J 2014, 33(6):630-636.
99. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361(25):2414-2423.
100. Nolan T., Richmond P.C., Formica N.T., Höschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26(50):6383-6391.
101. Carmona A., Omeñaca F., Tejedor J.C., Merino J.M., Vaman T., Dieussaert I., et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010, 28(36):5837-5844.
102. Launay O., Duval X., Fitoussi S., Jilg W., Kerdpanich A., Montellano M., et al. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infect Dis 2013, 13:435.
103. Poder A., Simurka P., Li P., Roy-Ghanta S., Vaughn D. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. Vaccine 2014, 32(9):1121-1129.
104. Pellegrini M., Nicolay U., Lindert K., Groth N., Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009, 27(49):6959-6965.
105. Black S., Della Cioppa G., Malfroot A., Nacci P., Nicolay U., Pellegrini M., et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 2010, 28(45):7331-7336.
106. Esposito S., Pugni L., Daleno C., Ronchi A., Valzano A., Serra D., et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 2011, 127(5):e1161-e1168.
107. Block S.L., Falloon J., Hirschfield J.A., Krilov L.R., Dubovsky F., Yi T., et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012, 31(7):745-751.
108. Knuf M., Leroux-Roels G., Rümke H.C., Abarca K., Rivera L., Lattanzi M., et al. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived. A/H1N1 pandemic influenza vaccine in children 6-35 months of age. Pediatr Infect Dis J 2014, 33(12):e320-e329.
109. Nolan T., Bravo L., Ceballos A., Mitha E., Gray G., Quiambao B., et al. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children. Vaccine 2014, 32(46):6146-6156.
110. Stockwell M.S., Broder K., LaRussa P., Lewis P., Fernandez N., Sharma D., et al. Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine. JAMA Pediatr 2014, 168(3):211-219.
111. American Academy of Pediatrics (AAP); Subcommittee on Febrile Seizures Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics 2008, 121(6):1281-1286.
112. American Academy of Pediatrics (AAP); Subcommittee on Febrile Seizures Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics 2011, 127(2):389-394.
113. Teng D., Dayan P., Tyler S., Hauser W.A., Chan S., Leary L., et al. Risk of intracranial pathologic conditions requiring emergency intervention after a first complex febrile seizure episode among children. Pediatrics 2006, 117(2):304-308.
114. Mewasingh L.D. Febrile seizures. Clin Evid (Online) 2014, 2014.
115. Vestergaard M., Christensen J. Register-based studies on febrile seizures in Denmark. Brain Dev 2009, 31(5):372-377.
116. Saghazadeh A., Mastrangelo M., Rezaei N. Genetic background of febrile seizures. Rev Neurosci 2014, 25(1):129-161.
117. Principi N., Esposito S. Vaccines and febrile seizures. Expert Rev Vaccines 2013, 12(8):885-892.
118. Verbeek N.E., Jansen F.E., Vermeer-de Bondt P.E., de Kovel C.G., van Kempen M.J., Lindhout D., et al. Etiologies for seizures around the time of vaccination. Pediatrics 2014, 134(4):658-666.
119. Bonhoeffer J., Menkes J., Gold M.S., de Souza-Brito G., Fisher M.C., Halsey N., et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004, 22(5-6):557-562.
120. McMahon A.W., Iskander J., Haber P., Chang S., Woo E.J., Braun M.M., et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics 2005, 115(2):453-460.
121. Rosenberg M., Sparks R., McMahon A., Iskander J., Campbell J.D., Edwards K.M. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine 2009, 27(32):4278-4283.
122. Muhammad R.D., Haber P., Broder K.R., Leroy Z., Ball R., Braun M.M., et al. Adverse events following trivalent inactivated influenza vaccination in children: analysis of the vaccine adverse event reporting system. Pediatr Infect Dis J 2011, 30(1):e1-e8.
123. France E.K., Glanz J.M., Xu S., Davis R.L., Black S.B., Shinefield H.R., et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med 2004, 158(11):1031-1036.
124. Hambidge S.J., Glanz J.M., France E.K., McClure D., Xu S., Yamasaki K., et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 2006, 296(16):1990-1997.
125. Goodman M.J., Nordin J.D., Harper P., DeFor T., Zhou X. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. Pediatrics 2006, 117(5):e821-e826.
126. Glanz J.M., Newcomer S.R., Hambidge S.J., Daley M.F., Narwaney K.J., Xu S., et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med 2011, 165(8):749-755.
127. Nazareth I., Tavares F., Rosillon D., Haguinet F., Bauchau V. Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study. BMJ Open 2013, 3(2).
128. Armstrong P.K., Dowse G.K., Effler P.V., Carcione D., Blyth C.C., Richmond P.C., et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011, 1(1):e000016.
129. Mahajan D., Cook J., McIntyre P.B., Macartney K., Menzies R.I. Annual report: surveillance of adverse events following immunisation in Australia, 2010. Commun Dis Intell Q Rep 2011, 35(4):263-280.
130. Wood N., Sheppeard V., Cashman P., Palasanthiran P., Casacelli M., Cannings K., et al. Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia. Pediatr Infect Dis J 2012, 31(2):199-202.
131. Salisbury D.M. Letter to general practitioners 2010, Available at: https://www.gov.uk/government/publications/seasonal-flu-immunisation-programme-2011-12.
132. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303(1):37-46.
133. Cook J. Australian experience with non-adjuvant H1N1 vaccine (Panvax and Panvax Junior). Aust Prescr 2010, 33(4):121-123.
134. Lambert S.B., Chuk L.M.R., Nissen M.D., Nolan T.M., McVernon J., Booy R., et al. Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents. Influenza Other Respir Viruses 2013, 7(5):676-685.
135. Nolan T., Richmond P.C., McVernon J., Skeljo M.V., Hartel G.F., Bennet J., et al. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respir Viruses 2009, 3(6):315-325.
136. Petousis-Harris H., Poole T., Booy R., Turner N. Fever following administration of two inactivated influenza vaccines-A survey of parents of New Zealand infants and children 5 years of age and under. Vaccine 2011, 29(16):2933-2937.
137. Kaczmarek M.C., Duong U.T., Ware R.S., Lambert S.B., Kelly H.A. The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged (greater-than or equal to)6 months to <36 months: a comparison of published and unpublished studies. Vaccine 2013, 31(46):5359-5365.
138. Maraskovsky E., Rockman S., Dyson A., Koernig S., Becher D., Morelli A.B., et al. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine. Vaccine 2012, 30(51):7400-7406.
139. Rockman S., Becher D., Dyson A., Koernig S., Morelli A.B., Barnden M., et al. Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine. Vaccine 2014, 32(30):3869-3876.
140. Rockman S., Dyson A., Koernig S., Becher D., Ng M., Morelli A.B., et al. Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events. Vaccine 2014, 32(30):3861-3868.
141. World Health Organization Global Advisory Committee on Vaccine Safety, 11-12 December 2013. Wkly Epidemiol Rec 2014, 89(7):53-60.
142. Kelly H.A., Skowronski D.M., de Serres G., Effler P.V. Adverse events associated with 2010 CSL and other inactivated influenza vaccines. Med J Aust 2011, 195(6):318-320.
143. Liang X.F., Li L., Liu D.W., Li K.L., Wu W.D., Zhu B.P., et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med 2011, 364(7):638-647.
144. Folkenberg M., Callreus T., Svanstrom H., Valentiner-Branth P., Hviid A. Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010. Vaccine 2011, 29(6):1180-1184.
145. Kraigher A., Ucakar V. Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009/10. Vaccine 2010, 28(33):5467-5472.
146. van Puijenbroek E.P., Broos N., van Grootheest K. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands. Drug Saf 2010, 33(12):1097-1108.
147. Stowe J., Andrews N., Bryan P., Seabroke S., Miller E. Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study. Vaccine 2011, 29(51):9467-9472.
148. Leroy Z., Broder K., Menschik D., Shimabukuro T., Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. Vaccine 2012, 30(11):2020-2023.
149. Tse A., Tseng H.F., Greene S.K., Vellozzi C., Lee G.M. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012, 30(11):2024-2031.
150. Tse A.C., Tseng H.F., Greene S.K., Vellozzi C., Weintraub E., McCarthy N., et al. Risk of febrile seizures in children following trivalent inactivated influenza vaccine in the vaccine safety datalink project, 2010-2011. Pharmacoepidemiol Drug Saf 2012, 21:365-366.
151. Duffy J. Seizures following administration of multiple vaccines: a VSD study. Slide presentation at: meeting of the Advisory Committee on Immunization Practices (ACIP) 2014.
152. Kawai A.T., Li L., Kulldorff M., Vellozzi C., Weintraub E., Baxter R., et al. Absence of associations between influenza vaccines and increased risks of seizures. Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season. Pharmacoepidemiol Drug Saf 2014, 23(5):548-553.
153. Van Buynder P.G., Frosst G., Van Buynder J.L., Tremblay F.W., Ross A., Jardine C., et al. Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination. Influenza Other Respir Viruses 2013, 7(2):184-190.
154. Lum L.C., Borja-Tabora C.F., Breiman R.F., Vesikari T., Sablan B.P., Chay O.M., et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 2010, 28(6):1566-1574.
155. Reynales H., Astudillo P., de Valliere S., Hatz C., Schlagenhauf P., Rath B., et al. A prospective observational safety study on MF59 (registered trademark) adjuvanted cell culture-derived vaccine. Celtura(registered trademark) during the A/H1N1 (2009) influenza pandemic. Vaccine 2012, 30(45):6436-6443.
156. Haber P., Moro P.L., McNeil M.M., Lewis P., Woo E.J., Hughes H., et al. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013. Vaccine 2014, 32(48):6499-6504.
157. ® Quadrivalent (Influenza vaccine live, intranasal), intranasal spray, 2014-2015 formula: package insert 2014.
158. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356(7):685-696. [Erratum in: N Engl J Med 2007;356(12):1283].
159. Tennis P., Toback S.L., Andrews E., McQuay L.J., Ambrose C.S. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. Vaccine 2011, 29(31):4947-4952.
160. Tennis P., Toback S.L., Andrews E.B., McQuay L.J., Ambrose C.S. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season. Vaccine 2012, 30(42):6099-6102.
161. McElhaney J.E., Beran J., Devaster J.M., Esen M., Launay O., Leroux-Roels G., et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013, 13(6):485-496.
162. World Health Organization/Global Vaccine Safety Information sheet: observed rate of vaccine reactions - influenza vaccine 2012, Available at: http://www.who.int/vaccine_safety/initiative/tools/Influenza_Vaccine_rates_information_sheet.pdf?ua=1 [accessed 26.05.15].
163. Margolis K.L., Nichol K.L., Poland G.A., Pluhar R.E. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. JAMA 1990, 264(9):1139-1141. [Erratum in: JAMA 1991;265(21):2810].
164. Margolis K.L., Poland G.A., Nichol K.L., MacPherson D.S., Meyer J.D., Korn J.E., et al. Frequency of adverse reactions after influenza vaccination. Am J Med 1990, 88(January (1)):27-30.
165. Nichol K.L., Margolis K.L., Lind A., Murdoch M., McFadden R., Hauge M., et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med 1996, 156(14):1546-1550.
166. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007, 25(44):7656-7663.
167. Beran J., Peeters M., Dewé W., Raupachová J., Hobzová L., Devaster J.M. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013, 13:224.
168. Vellozzi C., Broder K.R., Haber P., Guh A., Nguyen M., Cano M., et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31 2010. Vaccine 2010, 28(45):7248-7255.
169. Brady R.C., Hu W., Houchin V.G., Eder F.S., Jackson K.C., Hartel G.F., et al. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children. Vaccine 2014, 32(52):7141-7147.
170. Tregnaghi M.W., Stamboulian D., Vanadía P.C., Tregnaghi J.P., Calvari M., Fragapane E., et al. Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study. Viral Immunol 2012, 25(3):216-225.
171. Monto A.S., Gravenstein S., Elliott M., Colopy M., Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000, 160(21):3243-3247.
172. Beigel J.H. Influenza. Crit Care Med 2008, 36(9):2660-2666.
173. Hoek K.L., Samir P., Howard L.M., Niu X., Prasad N., Galassie A., et al. A cell-based systems biology assessment of human blood to monitor immune responses after influenza vaccination. PLOS ONE 2015, 10(2):e0118528.
174. Obermoser G., Presnell S., Domico K., Xu H., Wang Y., Anguiano E., et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 2013, 38(4):831-844.
175. Ramakrishnan A., Althoff K.N., Lopez J.A., Coles C.L., Bream J.H. Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines. Cytokine 2012, 60(3):661-666.
176. Christian L.M., Iams J.D., Porter K., Glaser R. Inflammatory responses to trivalent influenza virus vaccine among pregnant women. Vaccine 2011, 29(48):8982-8987.
177. Christian L.M., Porter K., Karlsson E., Schultz-Cherry S., Iams J.D. Serum proinflammatory cytokine responses to influenza virus vaccine among women during pregnancy versus non-pregnancy. Am J Reprod Immunol 2013, 70(1):45-53.
178. Fink C.W. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995, 22(8):1566-1569.
179. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet 2007, 369(9563):767-778.
180. Angeles-Han S., Prahalad S. The genetics of juvenile idiopathic arthritis: what is new in 2010?. Curr Rheumatol Rep 2010, 12(2):87-93.
181. Berkun Y., Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 2010, 9(5):A319-A324.
182. Aslan M., Kasapcopur O., Yasar H., Polat E., Saribas S., Cakan H., et al. Do infections trigger juvenile idiopathic arthritis?. Rheumatol Int 2011, 31(2):215-220.
183. Shimizu M., Ueno K., Yachie A. Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab. Clin Vaccine Immunol 2012, 19(10):1700-1702.
184. Asakawa J., Kobayashi S., Kaneda K., Ogasawara H., Sugawara M., Yasuda M., et al. Reactive arthritis after influenza vaccination: report of a case. Mod Rheumatol 2005, 15(4):283-285.
185. Yoshioka K., Fujimoto S., Oba H., Minami M., Aoki T. Onset of adult-onset Still's disease following influenza vaccination. Mod Rheumatol 2011, 21(4):432-435.
186. De Nardo P., Bellagamba R., Corpolongo A., Gentilotti E., Taglietti F., Rosati S., et al. Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report. Clin Vaccine Immunol 2013, 20(5):761-764.
187. Chalmers A., Scheifele D., Patterson C., Williams D., Weber J., Shuckett R., et al. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 1994, 21(7):1203-1206.
188. Harrison B.J., Thomson W., Pepper L., Ollier W.E., Chakravarty K., Barrett E.M., et al. Patients who develop inflammatory polyarthritis (IP) after immunization are clinically indistinguishable from other patients with IP. Br J Rheumatol 1997, 36(3):366-369.
189. Oren S., Mandelboim M., Braun-Moscovici Y., Paran D., Ablin J., Litinsky I., et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008, 67(7):937-941.
190. Aikawa N.E., Campos L.M., Silva C.A., Carvalho J.F., Saad C.G., Trudes G., et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012, 39(1):167-173.
191. Toplak N., Subelj V., Kveder T., Cucnik S., Prosenc K., Trampus-Bakija A., et al. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2012, 30(3):436-444.
192. Gabay C., Bel M., Combescure C., Ribi C., Meier S., Posfay-Barbe K., et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011, 63(6):1486-1496.
193. Elkayam O., Amir S., Arad U., Wollman J., Brill A., Paran D., et al. The cellular response to vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res 2011, 63(10 Suppl):1.
194. Saad C.G., Borba E.F., Aikawa N.E., Silva C.A., Pereira R.M., Calich A.L., et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011, 70(6):1068-1073.
195. Shinoki T., Hara R., Kaneko U., Miyamae T., Imagawa T., Mori M., et al. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol 2012, 22(6):871-876.
196. Ray P., Black S., Shinefield H., Dillon A., Carpenter D., Lewis E., et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age. Vaccine 2011, 29(38):6592-6597.
197. Bardage C., Persson I., Ortqvist A., Bergman U., Ludvigsson J.F., Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 2011, 343:d5956.
198. Baxter R., Toback S.L., Sifakis F., Hansen J., Bartlett J., Aukes L., et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. Vaccine 2012, 30(19):2989-2998.
199. Bengtsson C., Kapetanovic M.C., Källberg H., Sverdrup B., Nordmark B., Klareskog L., et al. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis 2010, 69(10):1831-1833.
200. Bodor M., Montalvo E. Vaccination-related shoulder dysfunction. Vaccine 2007, 25(4):585-587.
201. Atanasoff S., Ryan T., Lightfoot R., Johann-Liang R. Shoulder injury related to vaccine administration (SIRVA). Vaccine 2010, 28(51):8049-8052.
202. Okur G., Chaney K.A., Lomasney L.M. Magnetic resonance imaging of abnormal shoulder pain following influenza vaccination. Skelet Radiol 2014, 43(9):1325-1331.
203. Barnes M.G., Ledford C., Hogan K. A "needling" problem: shoulder injury related to vaccine administration. J Am Board Fam Med 2012, 25(6):919-922.
204. Shaikh M.F., Baqai T.J., Tahir H. Acute brachial neuritis following influenza vaccination. BMJ Case Rep 2012.
205. Kuether G., Dietrich B., Smith T., Peter C., Gruessner S. Atraumatic osteonecrosis of the humeral head after influenza A-(H1N1) v-2009 vaccination. Vaccine 2011, 29(40):6830-6833.
206. Foster S., Davis M.V. Vaccine administration: preventing serious shoulder injuries. J Am Pharm Assoc 2013, 53(1):102-103.
207. Cook I.F. Subdeltoid/subacromial bursitis associated with influenza vaccination. Hum Vaccin Immunother 2014, 10(3):605-606.
208. Vucic S., Kiernan M.C., Cornblath D.R. Guillain-Barré syndrome: an update. J Clin Neurosci 2009, 16(6):733-741.
209. Willison H.J. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005, 10(2):94-112.
210. Vellozzi C., Iqbal S., Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis 2014, 58(8):1149-1155.
211. Tam C.C., O'Brien S.J., Petersen I., Islam A., Hayward A., Rodrigues L.C. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS ONE 2007, 2(4):e344.
212. Stowe J., Andrews N., Wise L., Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol 2009, 169(3):382-388.
213. Rees J.H., Soudain S.E., Gregson N.A., Hughes R.A. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995, 333(21):1374-1379.
214. Mizoguchi K. Anti-GQ1b IgG antibody activities related to the severity of Miller Fisher syndrome. Neurol Res 1998, 20(7):617-624.
215. Ellenberg S.S., Braun M.M. Monitoring the safety of vaccines: assessing the risks. Drug Saf 2002, 25(3):145-152.
216. Schonberger L.B., Bregman D.J., Sullivan-Bolyai J.Z., Keenlyside R.A., Ziegler D.W., Retailliau H.F., et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979, 110(2):105-123.
217. Salmon D.A., Proschan M., Forshee R., Gargiullo P., Bleser W., Burwen D.R., et al. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 2013, 381(9876):1461-1468.
218. Langmuir A.D. Guillain-Barré syndrome: the swine influenza virus vaccine incident in the United States of America, 1976-77: preliminary communication. J R Soc Med 1979, 72(9):660-669.
219. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012, 61(32):613-618.
220. Johnson D.E. Guillain-Barré syndrome in the US Army. Arch Neurol 1982, 39(1):21-24.
221. Institute of Medicine Immunization safety review: influenza vaccines and neurological complications 2003, The National Academies Press, Washington, DC.
222. Lasky T., Terracciano G.J., Magder L., Koski C.L., Ballesteros M., Nash D., et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998, 339(25):1797-1802.
223. Juurlink D.N., Stukel T.A., Kwong J., Kopp A., McGeer A., Upshur R.E., et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006, 166(20):2217-2221.
224. Nachamkin I., Shadomy S.V., Moran A.P., Cox N., Fitzgerald C., Ung H., et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis 2008, 198(2):226-233.
225. Wang D.J., Boltz D.A., McElhaney J., McCullers J.A., Webby R.J., Webster R.G. No evidence of a link between influenza vaccines and Guillain-Barre syndrome-associated antiganglioside antibodies. Influenza Other Respir Viruses 2012, 6(3):159-166.
226. Lei T., Siu K.L., Kok K.H., Chan K.H., Chan E.Y., Hung I.F., et al. Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. Vaccine 2012, 30(16):2605-2610.
227. Sejvar J.J., Kohl K.S., Gidudu J., Amato A., Bakshi N., Baxter R., et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011, 29(3):599-612.
228. Sejvar J.J., Pfeifer D., Schonberger L.B. Guillain-barré syndrome following influenza vaccination: causal or coincidental?. Curr Infect Dis Rep 2011, 13(4):387-398.
229. Brostoff S.W., White T.M. Absence of P2 protein in swine flu vaccines. JAMA 1982, 247(4):495.
230. Hjorth R.N., Bonde G.M., Piner E., Hartzell R.W., Rorke L.B., Rubin B.A. Experimental neuritis induced by a mixture of neural antigens and influenza vaccines. A possible model for Guillain-Barré syndrome. J Neuroimmunol 1984, 6(1):1-8.
231. Kramarz P., DeStefano F., Gargiullo P.M., Davis R.L., Chen R.T., Mullooly J.P., et al. Does influenza vaccination exacerbate asthma? Analysis of a large cohort of children with asthma. Vaccine Safety Datalink Team. Arch Fam Med 2000, 9(7):617-623.
232. Burwen D.R., Sandhu S.K., MaCurdy T.E., Kelman J.A., Gibbs J.M., Garcia B., et al. Surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2009-2010. Am J Public Health 2012, 102(10):1921-1927.
233. Greene S.K., Rett M., Weintraub E.S., Li L., Yin R., Amato A.A., et al. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010. Am J Epidemiol 2012, 175(11):1100-1109.
234. Polakowski L.L., Sandhu S.K., Martin D.B., Ball R., Macurdy T.E., Franks R.L., et al. Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol 2013, 178(6):962-973.
235. Tokars J.I., Lewis P., DeStefano F., Wise M., Viray M., Morgan O., et al. The risk of Guillain-Barré syndrome associated with influenza A (H1N1) 2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from self-controlled analyses. Pharmacoepidemiol Drug Saf 2012, 21(5):546-552.
236. Whitaker H.J., Farrington C.P., Spiessens B., Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006, 25(10):1768-1797.
237. Carr S., Allison K.J., Van De Velde L.A., Zhang K., English E.Y., Iverson A., et al. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis 2011, 204(10):1475-1482.
238. CDC Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010. Morb Mortal Wkly Rep 2010, 59(21):657-661.
239. Dodd C.N., Romio S.A., Black S., Vellozzi C., Andrews N., Sturkenboom M., et al. International collaboration to assess the risk of Guillain Barré syndrome following influenza A (H1N1) 2009 monovalent vaccines. Vaccine 2013, 31(40):4448-4458.
240. Prestel J., Volkers P., Mentzer D., Lehmann H.C., Hartung H.P., Keller-Stanislawski B., et al. Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany. Pharmacoepidemiol Drug Saf 2014, 23(11):1192-1204.
241. Huang W.T., Yang H.W., Liao T.L., Wu W.J., Yang S.E., Chih Y.C., et al. Safety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study. PLOS ONE 2013, 8(3):e58827.
242. Galeotti F., Massari M., D'Alessandro R., Beghi E., Chiò A., Logroscino G., et al. Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination. Eur J Epidemiol 2013, 28(5):433-444.
243. Greene S.K., Rett M.D., Vellozzi C., Li L., Kulldorff M., Marcy S.M., et al. Guillain-Barré syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009-2011. PLOS ONE 2013, 8(6):e67185.
244. Kwong J.C., Vasa P.P., Campitelli M.A., Hawken S., Wilson K., Rosella L.C., et al. Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis 2013, 13(9):769-776.
245. Reik L. Neurological complications of immunization. Neurol Infect Epidemiol 1997, 2(2):69-98.
246. Ekstrand J.J. Neurologic complications of influenza. Semin Pediatr Neurol 2012, 19(3):96-100.
247. Sejvar J.J., Kohl K.S., Bilynsky R., Blumberg D., Cvetkovich T., Galama J., et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5771-5792.
248. Behan P.O. Acute disseminated encephalomyelitis: postinfectious, postimmunization and variant forms. Expert Rev Neurother 2009, 9(9):1321-1329.
249. Huynh W., Cordato D.J., Kehdi E., Masters L.T., Dedousis C. Post-vaccination encephalomyelitis: literature review and illustrative case. J Clin Neurosci 2008, 15(12):1315-1322.
250. Marchioni E., Tavazzi E., Minoli L., Del Bue S., Ferrante P., Piccolo G., et al. Acute disseminated encephalomyelitis. Neurol Sci 2008, 29(Suppl. 2):S286-S288.
251. Mihai C., Jubelt B. Post-infectious encephalomyelitis. Curr Neurol Neurosci Rep 2005, 5(6):440-445.
252. Ekmekc Di, Gencer M., Tutkavul K., Varlibas F., Tireli H. Acute disseminated encephalomyelitis after H1N1 infection. Neurology 2010, 17(Suppl. 3):504.
253. Hemachudha T., Griffin D.E., Giffels J.J., Johnson R.T., Moser A.B., Phanuphak P. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. N Engl J Med 1987, 316(7):369-374.
254. Lane J.M., Millar J.D. Routine childhood vaccination against smallpox reconsidered. N Engl J Med 1969, 281(22):1220-1224.
255. Hoshino T., Uchiyama Y., Ito E., Osawa S., Ohashi T. Simultaneous development of acute disseminated encephalomyelitis and Guillain-Barré syndrome associated with H1N1 09 influenza vaccination. Intern Med 2012, 51(12):1595-1598.
256. Hopkins S.E., Tillema J.M., DeGrauw T. Variability in infectious disease testing for patients with acute disseminated encephalomyelitis. Ann Neurol 2010, 68(Suppl. 14):S122.
257. Masoodi I., Farooq O., Ahmad I., Bhat M.Y., Ahmad N., Wani H.U., et al. Acute disseminated encephalomyelitis as the first presentation of CNS tuberculosis: report of a case with brief review. German Med Sci 2010, 8:Doc32.
258. Persson I., Granath F., Askling J., Ludvigsson J.F., Olsson T., Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med 2014, 275(2):172-190.
259. Isai A., Durand J., Le Meur S., Hidalgo-Simon A., Kurz X. Autoimmune disorders after immunisation with Influenza A/H1N1 vaccines with and without adjuvant: EudraVigilance data and literature review. Vaccine 2012, 30(49):7123-7129.
260. Sauve L.J., Bettinger J., Vaudry W., Moore D., Scheifele D., Halperin S., et al. IMPACT network active surveillance for adverse events following adjuvanted pandemic influenza vaccine in Canadian children. Can J Infect Dis Med Microbiol 2010, 21(4):180.
261. Sacheli A., Bauer R. Influenza vaccine-induced CNS demyelination in a 50-year-old male. Am J Case Rep 2014, 15:368-373.
262. Williams S.E., Klein N.P., Halsey N., Dekker C.L., Baxter R.P., Marchant C.D., et al. Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009. Vaccine 2011, 29(40):6920-6927.
263. Williams S.E., Pahud B.A., Vellozzi C., Donofrio P.D., Dekker C.L., Halsey N., et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine 2011, 29(46):8302-8308.
264. Pena J.A., Lotze T.E. Pediatric multiple sclerosis: current concepts and consensus definitions. Autoimmune Dis 2013, 2013:673947.
265. Sundqvist E., Sundström P., Lindén M., Hedström A.K., Aloisi F., Hillert J., et al. Epstein-Barr virus and multiple sclerosis: interaction with HLA. Genes Immun 2012, (1):14-20.
266. DeStefano F., Verstraeten T., Jackson L.A., Okoro C.A., Benson P., Black S.B., et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003, 60(4):504-509.
267. Hernán M.A., Jick S.S., Olek M.J., Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004, 63(5):838-842.
268. Ramagopalan S.V., Valdar W., Dyment D.A., DeLuca G.C., Yee I.M., Giovannoni G., et al. Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology 2009, 32(4):257-262.
269. Zorzon M., Zivadinov R., Nasuelli D., Dolfini P., Bosco A., Bratina A., et al. Risk factors of multiple sclerosis: a case-control study. Neurol Sci 2003, 24(4):242-247.
270. Ho T.Y., Huang K.Y., Huang T.T., Huang Y.S., Ho H.C., Chou P., et al. The impact of influenza vaccinations on the adverse effects and hospitalization rate in the elderly: a national based study in an Asian country. PLoS ONE 2012, 7(11):e50337.
271. Farez M.F., Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011, 258(7):1197-1206.
272. Miller A.E., Morgante L.A., Buchwald L.Y., Nutile S.M., Coyle P.K., Krupp L.B., et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 1997, 48(2):312-314.
273. Confavreux C., Suissa S., Saddier P., Bourdès V., Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001, 344(5):319-326. Vaccines in Multiple Sclerosis Study Group.
274. Mokhtarian F., Shirazian D., Morgante L., Miller A., Grob D., Lichstein E. Influenza virus vaccination of patients with multiple sclerosis. Mult Scler 1997, 3(4):243-247.
275. Myers L.W., Ellison G.W., Lucia M., Novom S., Holevoet M., Madden D., et al. Swine influenza virus vaccination in patients with multiple sclerosis. J Infect Dis 1977, 136(Suppl):S546-S554.
276. Bamford C.R., Sibley W.A., Laguna J.F. Swine influenza vaccination in patients with multiple sclerosis. Arch Neurol 1978, 35(4):242-243.
277. Auriel E., Gaoth A., Regev K., Karni A. Seasonal and H1N1 v influenza vaccines in MS: safety and compliance. J Neuro Sci 2012, 314:102-103.
278. McNicholas N., Chataway J. Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J Neurol 2011, 258(8):1545-1547.
279. Partinen M., Kornum B.R., Plazzi G., Jennum P., Julkunen I., Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol 2014, 13(6):600-613.
280. Poli F., Overeem S., Lammers G.J., Plazzi G., Lecendreux M., Bassetti C.L., et al. Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine 2013, 31(6):994-1007.
281. Ahmed S.S., Schur P.H., MacDonald N.E., Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 2014, 50:1-11.
282. Masoudi S., Ploen D., Kunz K., Hildt E. The adjuvant component α-tocopherol triggers via modulation of Nrf2 the expression and turnover of hypocretin in vitro and its implication to the development of narcolepsy. Vaccine 2014, 32(25):2980-2988.
283. Johansen K. The roles of influenza virus antigens and the AS03 adjuvant in the 2009 pandemic vaccine associated with narcolepsy needs further investigation. Dev Med Child Neurol 2014, 56(11):1041-1042.
284. Durrieu G., Caillet A., Faucher A., Jacquet A., Ouaret S., Auriche P., et al. Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. Fundamental and Clinical Pharmacology 2011. Societe Francaise de Pharmacologie et de Therapeutique 2011, 25(Suppl. 1):72.
285. Partinen M. Increased incidence of narcolepsy after the A/H1N1 pandemic influenza vaccination campaign in the Nordic countries. J Sleep Res 2012, 21(Suppl. 1):83.
286. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012, 7(3):e33536.
287. National Institute for Health and Welfare Increased risk of narcolepsy observed also among adults vaccinated with Pandemrix in Finland 2013, http://www.thl.fi/en_US/web/en/pressrelease?id=33516 [accessed 28.05.13].
288. European Centre for Disease Prevention and Control Narcolepsy in association with pandemic influenza vaccination (a multi-county European epidemiological investigation) 2012, ECDC, Stockholm.
289. Wijnans L., Lecomte C., de Vries C., Weibel D., Sammon C., Hviid A., et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013, 31(8):1246-1254.
290. ®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011, 43(9):702-706.
291. McCarthy N.L., Gee J., Lin N.D., Thyagarajan V., Pan Y., Su S., et al. Evaluating the safety of influenza vaccine using a claims-based health system. Vaccine 2013, 31(50):5975-5982.
292. Duffy J., Weintraub E., Vellozzi C., DeStefano F. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States. Neurology 2014, 83(20):1823-1830. Vaccine Safety Datalink.
293. Han F. Sleepiness that cannot be overcome: narcolepsy and cataplexy. Respirology 2012, 17(8):1157-1165.
294. Melén K., Partinen M., Tynell J., Sillanpää M., Himanen S.L., Saarenpää-Heikkilä O., et al. No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland. PLOS ONE 2013, 8(8):e68402.
295. Vaarala O., Vuorela A., Partinen M., Baumann M., Freitag T.L., Meri S., et al. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk. PLOS ONE 2014, 9(12):e114361.
296. De la Herrán-Arita A.K., Kornum B.R., Mahlios J., Jiang W., Lin L., Hou T., et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 2013, 5(216):216ra176.
297. Rath B., Linder T., Cornblath D., Hudson M., Fernandopulle R., Hartmann K., et al. All that palsies is not Bell's - the need to define Bell's palsy as an adverse event following immunization. Vaccine 2007, 26(1):1-14.
298. Beal M.F., Hauser S.L. Chapter 376. Trigeminal neuralgia, Bell's Palsy, and other cranial nerve disorders. Harrison's principles of internal medicine 2012, McGraw-Hill, New York. http://www.accessmedicine.com/, 18th ed. D.L. Longo, A.S. Fauci, D.L. Kasper, S.L. Hauser, J.L. Jameson, J. Loscalzo (Eds.).
299. Couch R.B., Nasal vaccination Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med 2004, 350(9):860-861.
300. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(9):896-903.
301. Lewis D.J., Huo Z., Barnett S., Kromann I., Giemza R., Galiza E., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009, 4(9):e6999.
302. Schwab M.E., Suda K., Thoenen H. Selective retrograde transsynaptic transfer of a protein, tetanus toxin, subsequent to its retrograde axonal transport. J Cell Biol 1979, 82(3):798-810.
303. Zurbriggen R., Metcalfe I.C., Glück R., Viret J.F., Moser C. Nonclinical safety evaluation of Escherichia coli heat-labile toxin mucosal adjuvant as a component of a nasal influenza vaccine. Expert Rev Vaccines 2003, 2(2):295-304.
304. Chou C.H., Liou W.P., Hu K.I., Loh C.H., Chou C.C., Chen Y.H. Bell's palsy associated with influenza vaccination: two case reports. Vaccine 2007, 25(15):2839-2841.
305. Lessa R., Castillo M., Azevedo R., Azevedo F., Azevedo H. Neurological complications after H1N1 influenza vaccination: magnetic resonance imaging findings. Arq Neuropsiquiatr 2014, 72(7):496-499.
306. Greene S.K., Kulldorff M., Lewis E.M., Li R., Yin R., Weintraub E.S., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010, 171(2):177-188.
307. Yih W.K., Lee G.M., Lieu T.A., Ball R., Kulldorff M., Rett M., et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol 2012, 175(11):1120-1128.
308. Teachey D.T., Lambert M.P. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr Clin North Am 2013, 60(6):1489-1511.
309. Neunert C.E., Buchanan G.R., Imbach P., Bolton-Maggs P.H., Bennett C.M., Neufeld E.J., et al. Participants. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008, 112(10):4003-4008.
310. McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am 2009, 23(6):1163-1175.
311. Mantadakis E., Farmaki E., Thomaidis S., Tsalkidis A., Chatzimichael A. A case of immune thrombocytopenic purpura after influenza vaccination: consequence or coincidence?. J Pediatr Hematol Oncol 2010, 32(6):e227-e229.
312. Oski F.A., Naiman J.L. Effect of live measles vaccine on the platelet count. N Engl J Med 1966, 275(7):352-356.
313. O'Leary S.T., Glanz J.M., McClure D.L., Akhtar A., Daley M.F., Nakasato C., et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics 2012, 129(2):248-255.
314. Kelton J.G. Vaccination-associated relapse of immune thrombocytopenia. JAMA 1981, 245(4):369-370.
315. Kaneko H., Ohkawara Y., Nomura K., Horiike S., Taniwaki M., et al. Relapse of idiopathic thrombocytopenic purpura caused by influenza A virus infection: a case report. J Infect Chemother 2004, 10:364-366.
316. Brodin-Sartorius A., Guebre-Egziabher F., Fouque D., Cozon G., Villar E., Laville M., et al. Recurrent idiopathic thrombotic thrombocytopenic purpura: a role for vaccination in disease relapse?. Am J Kidney Dis 2006, 48(3):e31-e34.
317. Grimaldi-Bensouda L., Michel M., Aubrun E., Leighton P., Viallard J.F., Adoue D., et al. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. Blood 2012, 120(25):4938-4944.
318. Villa M., Black S., Groth N., Rothman K.J., Apolone G., Weiss N.S., et al. Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of MF59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy. Am J Epidemiol 2013, 178(7):1139-1145.
319. Hur K., Cunningham F., Zhang R., Thakkar B., Eskridge M. Safety of the 2010-2011 influenza vaccinations in the Department of Veteran Affairs, Abstracts of the 28th ICPE 2012. Pharmacoepidemiol Drug Saf 2012, 361.
320. Luke C.J., Lakdawala S.S., Subbarao K. Chapter 18: influenza vaccine-live. Vaccine 2012, 294-311. Saunders, Philadelphia. 6th ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
321. Rudenko L.G., Slepushkin A.N., Monto A.S., Kendal A.P., Grigorieva E.P., Burtseva E.P., et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993, 168(4):881-887.
322. Fleming D.M., Crovari P., Wahn U., Klemola T., Schlesinger Y., Langussis A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25(10):860-869.
323. Ashkenazi S., Vertruyen A., Arístegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25(10):870-879.
324. CDC Advisory Committee on Immunization Practices (ACIP) recommends a preference for using the nasal spray flu vaccine. Media Statement. June 2014, 25. Available at: www.cdc.gov/media/releases/2014/s-acip.html0625.
325. Public Health England The Green Book - Influenza (Chapter 19 v8_0) 2014, Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/370735/Green_Book_Chapter_19_v8_0.pdf.
326. National Advisory Committee on Immunization (NACI) Statement on seasonal influenza vaccine for 2014-2015. Canada, Communicable Disease Report CCDR, ACS-4 2013, vol. 39. Available at: www.phac-aspc.gc.ca/naci-ccni/flu-grippe-eng.php#v.
327. Block S.L., Yogev R., Hayden F.G., Ambrose C.S., Zeng W., Walker R.E. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008, 26(38):4940-4946.
328. Vesikari T., Karvonen A., Korhonen T., Edelman K., Vainionpää R., Salmi A., et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006, 25(7):590-595.
329. Mallory R.M., Yi T., Ambrose C.S. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age. Vaccine 2011, 29(26):4322-4327.
330. Piedra P.A., Yan L., Kotloff K., Zangwill K., Bernstein D.I., King J., et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 2002, 110(4):662-672.
331. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994, 169(1):68-76.
332. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338(20):1405-1412.
333. Swierkosz E.M., Newman F.K., Anderson E.L., Nugent S.L., Mills G.B., Belshe R.B. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children. J Infect Dis 1994, 169(5):1121-1124.
334. Ambrose C.S., Yi T., Falloon J. An integrated, multi-study analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respir Viruses 2011, 5(6):389-397.
335. Bracco Neto H., Farhat C.K., Tregnaghi M.W., Madhi S.A., Razmpour A., Palladino G., et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009, 28(5):365-371.
336. Heymann P.W., Carper H.T., Murphy D.D., Platts-Mills T.A., Patrie J., McLaughlin A.P., et al. Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol 2004, 114(2):239-247.
337. Inoue Y., Shimojo N. Epidemiology of virus-induced wheezing/asthma in children. Front Microbiol 2013, 4:391.
338. Melendi G.A., Laham F.R., Monsalvo A.C., Casellas J.M., Israele V., Polack N.R., et al. Cytokine profiles in the respiratory tract during primary infection with human metapneumovirus, respiratory syncytial virus, or influenza virus in infants. Pediatrics 2007, 120(2):e410-e415.
339. Gern J.E., Martin M.S., Anklam K.A., Shen K., Roberg K.A., Carlson-Dakes K.T., et al. Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy. Pediatr Allergy Immunol 2002, 13(6):386-393.
340. Takeyama A., Hashimoto K., Sato M., Sato T., Tomita Y., Maeda R., et al. Clinical and epidemiologic factors related to subsequent wheezing after virus-induced lower respiratory tract infections in hospitalized pediatric patients younger than 3 years. Eur J Pediatr 2014, 173(7):959-966.
341. Triantafilou K., Triantafilou M. Ion flux in the lung: virus-induced inflammasome activation. Trends Microbiol 2014, 22(10):580-588.
342. Bergen R., Black S., Shinefield H., Lewis E., Ray P., Hansen J., et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004, 23(2):138-144.
343. Breiman R.F., Brooks W.A., Goswami D., Lagos R., Borja-Tabora C., Lanata C.F., et al. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. Vaccine 2009, 27(40):5472-5479.
344. Miller E.K., Dumitrescu L., Cupp C., Dorris S., Taylor S., Sparks R., et al. Atopy history and the genomics of wheezing after influenza vaccination in children 6-59 months of age. Vaccine 2011, 29(18):3431-3437.
345. Toback S.L., Ambrose C.S., Eaton A., Hansen J., Aukes L., Lewis N., et al. A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age. Vaccine 2013, 31(14):1812-1818.
346. Piedra P.A., Gaglani M.J., Riggs M., Herschler G., Fewlass C., Watts M., et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 2005, 116:e397-e407.
347. Redding G., Walker R.E., Hessel C., Virant F.S., Ayars G.H., Bensch G., et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2002, 21(1):44-48.
348. Gaglani M.J., Piedra P.A., Herschler G.B., Griffith M.E., Kozinetz C.A., Riggs M.W., et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 2004, 158(1):65-73.
349. King J.C., Fast P.E., Zangwill K.M., Weinberg G.A., Wolff M., Yan L., et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001, 20(12):1124-1131.
350. Levin M.J., Song L.Y., Fenton T., Nachman S., Patterson J., Walker R., et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008, 26(33):4210-4217.
351. Halasa N., Englund J.A., Nachman S., Weinberg G.A., Huber V.C., Allison K., et al. Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. Vaccine 2011, 29(24):4110-4115.
352. Boikos C., De Serres G., Lands L.C., Boucher F.D., Tapiéro B., Daigneault P., et al. Safety of live-attenuated influenza vaccination in cystic fibrosis. Pediatrics 2014, 134(4):e983-e991.
353. Slepushkin A.N., Obrosova-Serova N.P., Burtseva E.I., Rudenko L.G., Govorkova E.A., Vartanyan R.V., et al. Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia: I. Safety and efficacy in two Moscow schools, 1987/88. Vaccine 1993, 11(3):323-328.
354. Rudenko L.G., Lonskaya N.I., Klimov A.I., Vasilieva R.I., Ramirez A. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. Bull World Health Organ 1996, 74(1):77-84.
355. Kulkarni P.S., Raut S.K., Dhere R.M. A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac) in India. Hum Vaccin Immunother 2013, 9(1):122-124.
356. Ortiz J., Goswami D., Lewis K.D.C., Sharmeen A.T., Ahmed M., Rahman M., et al. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized clinical trial among children in urban Bangladesh. Vaccine 2014, [in revision].
357. Brooks A., et al. A randomized, double-blind, placebo-controlled trial on the clinical safety and efficacy of a single dose of trivalent seasonal live-attenuated influenza vaccine among children aged 24 through 59 months in Bangladesh. Vaccine 2015, [in revision].
358. Feldman S., Wright P.F., Webster R.G. Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole-virus. J Infect Dis 1985, 152(6):1212-1218.
359. Skowronski D.M., Hottes T.S., Chong M., De Serres G., Scheifele D.W., Ward B.J., et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics 2011, 128(2):e276-e289.
360. Domachowske J.B., Blatter M., Chandrasekaran V., Liu A., Jain V.K., Fries L. A randomized, controlled trial in children to assess the immunogenicity and safety of a thimerosal-free trivalent seasonal influenza vaccine. Pediatr Infect Dis J 2012, 31(6):605-615.
361. Dieleman J., Romio S., Johansen K., Weibel D., Bonhoeffer J., Sturkenboom M., et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011, 343:d3908.
362. Szakács A., Darin N., Hallböök T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013, 80(14):1315-1321.
363. O'Flanagan D., Barret A.S., Foley M., Cotter S., Bonner C., Crowe C., et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Euro Surveill 2014, 19(17):15-25.
364. Montplaisir J., Petit D., Quinn M.J., Ouakki M., Deceuninck G., Desautels A., et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLOS ONE 2014, 9(9):e108489.
365. Solberg O.D., Mack S.J., Lancaster A.K., Single R.M., Tsai Y., Sanchez-Mazas A., et al. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol 2008, 69(7):443-464. Supplemental materials available at: http://pypop.org/popdata/2008/maps/DQB1-0602.gif [accessed 04.06.14].
366. Arguedas A., Soley C., Abdelnour A., Sales V., Lindert K., Della Cioppa G., et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin 2011, 7(1):58-66.
367. Atmar R.L., Keitel W.A. Preventing pandemic influenza: an update on vaccine development. Infect Med 2007, 24(7):292-298.
368. Bart S.A., Hohenboken M., Della Cioppa G., Narasimhan V., Dormitzer P.R., Kanesa-Thasan N. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014, 6(234):234ra55.
369. Luo F.J., Yang L.Q., Ai X., Bai Y.H., Wu J., Li S.M., et al. Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial. Hum Vaccin Immunother 2013, 9(8):1725-1734.
370. Kanra G., Marchisio P., Feiterna-Sperling C., Gaedicke G., Lazar H., Durrer P., et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004, 23(4):300-306. [Erratum in: Pediatr Infect Dis J 2004;23(6):503].
371. Scheifele D.W., Ward B.J., Dionne M., Vanderkooi O., Langley J.M., Dobson S., et al. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr Infect Dis 2011, 30(5):402-407.
372. Solares A.R., Aragon C.G., Pivaral R.U., Prado-Cohrs D., Sales-Carmona V., Pellegrini M., et al. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children. J Infect Dev Ctries 2014, 8(9):1160-1168.
373. Van Buynder P.G., Frosst G., Van Buynder J.L., Tremblay F.W., Ross A., Jardine C., et al. Increased reactions to pediatric influenza vaccination following concomitant pneumococcal vaccination. Influenza Other Respir Viruses 2012, 7(2):184-190.
374. Messerschmitt P.J., Abdul-Karim W., Iannotti J.P., Gobezie R.G. Progressive osteolysis and surface chondrolysis of the proximal humerus following influenza vaccination. Orthopedics 2012, 35(2):e283-e286.
375. Robinson A.P., Harp C.T., Noronha A., Miller S.D. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol 2014, 122:173-189.
376. Krupp L.B., Tardieu M., Amato M.P., Banwell B., Chitnis T., Dale R.C., et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013, 19(10):1261-1267. 10.1177/1352458513484547.
377. Fujii K., Suyama M., Chiba K., Okunushi T., Oikawa J., Kohno Y. Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccine. Pediatr Int 2012, 54(4):539-541.
378. Karussis D., Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev 2014, 13(3):215-224.
379. Waubant E., Mowry E.M., Krupp L., Chitnis T., Yeh E.A., Kuntz N., et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 2011, 76(23):1989-1995.
380. Waubant E., Mowry E.M., Krupp L., Chitnis T., Yeh E.A., Kuntz N., et al. Antibody response to common viruses and human leukocyte antigen-DRB1 in pediatric multiple sclerosis. Mult Scler 2013, 19(7):891-895.
381. Farez M.F., Ysrraelit M.C., Fiol M., Correale J. H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study. Mult Scler 2012, 18(2):254-256.
382. Medical Products Agency (Lakemedelsverket) Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations: results of a case inventory study by the MPA in Sweden during 2009-2010 2011, Available at https://lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_pandermrix_110630.pdf.
383. Dauvilliers Y., Arnulf I., Lecendreux M., Monaca Charley C., Franco P., Drouot X., et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 2013, 136(Pt 8):2486-2496. Narcoflu-VF Study Group.
384. Dourmashkin R.R. What caused the 1918-30 epidemic of encephalitis lethargica?. J R Soc Med 1997, 90(9):515-520.
385. Sendi P., Locher R., Bucheli B., Battegay M. Intranasal influenza vaccine in a working population. Clin Infect Dis 2004, 38(7):974-980.
386. Zhou W., Pool V., DeStefano F., Iskander J.K., Haber P., Chen R.T. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. Pharmacoepidemiol Drug Saf 2004, 13(8):505-510. VAERS Working Group.
387. Stowe J., Andrews N., Wise L., Miller E. Bell's palsy and parenteral inactivated influenza vaccine. Hum Vaccin 2006, 2(3):110-112.
388. Lee S.T., Choe Y.J., Moon W.J., Choi J.W., Lee R. An adverse event following 2009 H1N1 influenza vaccination: a case of acute disseminated encephalomyelitis. Korean J Pediatr 2011, 54(10):422-424.
389. Black C., Kaye J.A., Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 2003, 55(1):107-111.
390. Miller E., Waight P., Farrington C.P., Andrews N., Stowe J., Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001, 84(3):227-229.
391. Rajantie J., Zeller B., Treutiger I., Rosthöj S. Vaccination associated thrombocytopenic purpura in children. Vaccine 2007, 25(10):1838-1840. NOPHO ITP Working Group and Five National Study Groups.
392. Liu C., Polakowski L., Divan H.A., Lu Y., Izurieta H., Selvam N. Idiopathic thrombocytopenic purpura after seasonal influenza vaccination. Pharmacoepidemiol Drug Saf 2014, 23(S1):1-497.
393. Steinhoff M.C., Halsey N.A., Fries L.F., Wilson M.H., King J., Burns B.A., et al. The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children. J Infect Dis 1991, 163(5):1023-1028.
394. Cano M. Interim influenza vaccine safety update: live attenuated influenza vaccine and inactivated influenza vaccine in persons <18 years of age, US, 2013-14. Presentation at ACIP Influenza Working Group Meeting 2014.
395. Ahmed S.S., Volkmuth W., Duca J., Corti L., Pallaoro M., Pezzicoli A., et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med 2015, 7(July (294)):294ra105. 10.1126/scitranslmed.aab2354.